Motley Bio

Motley Bio leverages its proprietary multi-omic sequencing technology to simultaneously profile DNA, RNA, and proteins (multi-omics) with a single assay producing a single readout, targeting applications in drug discovery, biomarker identification, and early cancer detection for biotech and pharmaceutical companies. The company sets itself apart by providing richer, more comprehensive data (single assay instead of multiple individual assays) at a lower cost and with lower internal data variability, while also demonstrating higher sensitivity and specificity for detecting mutations than competitors. A key distinguishing feature is its ability to generate this detailed multi-omic data from small amounts of patient samples, making it particularly valuable for early disease detection and drug development.